ReviewJournal of Cancer2020
CYP1B1 gene: Implications in glaucoma and cancer.
Review in Journal of Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Pooled it
- Deficiency in the Treatment Description of mTOR Inhibitor Resistance in Medulloblastoma, a Systematic Review.International journal of molecular sciences · 2021Pooled it
- Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers.Scientific reports · 2021Trial
- Semi-automated genomic newborn screening highlights complexities in reporting.NPJ genomic medicine · 2026Article
- The significance of immunogenic cell death related prognostic gene markers in colorectal cancer prognosis and antitumor immunity.Scientific reports · 2026Article
- Digoxin Attenuates Ocular Hypertension and Protects Trabecular Meshwork Cells via Ferroptosis Inhibition.Investigative ophthalmology & visual science · 2026Article
- Integrated machine learning and multi-omics analysis identifies CYP1B1 as a candidate target of orientin in intervertebral disc degeneration-associated low back pain.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Effects of Crocus sativus and its active constituents on cytochrome P450: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Comparative transcriptomic profiling of drug-metabolizing enzymes and drug transporters in rabbit ocular subtissues, liver, and duodenum.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Pathway-based cancer transcriptome deciphers a high-resolution intrinsic heterogeneity within bladder cancer classification.Journal of translational medicine · 2025Article
- Intrinsic disorder in CYP1B1 and its implications in primary congenital glaucoma pathogenesis.Journal of proteins and proteomics · 2025Article
- Insights intoLife (Basel, Switzerland) · 2025Review
- Effects of Berberis vulgaris, and its active constituent berberine on cytochrome P450: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Unraveling the role of heavy metals xenobiotics in cancer: a critical review.Discover oncology · 2024Review
- NNAT is a novel mediator of oxidative stress that suppresses ER + breast cancer.Molecular medicine (Cambridge, Mass.) · 2023Article
- Design of Cytochrome P450 1B1 InhibitorsJournal of medicinal chemistry · 2023Article
- Clinical role of CYP1B1 gene polymorphism in prediction of postoperative chemotherapy efficacy in NSCLC based on individualized health model.Open life sciences · 2023Article
- Whole-exome sequencing analysis in a case of primary congenital glaucoma due to the partial uniparental isodisomy.Genomics & informatics · 2022Article
- Association of Healthy Diet and Physical Activity With Breast Cancer: Lifestyle Interventions and Oncology Education.Frontiers in public health · 2022Review
- Cytochrome P450 1B1 Overexpression in Cervical Cancers: Cross-sectional Study.Interactive journal of medical research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a serious disease that can lead to irreversible loss of vision. Patients with primary congenital glaucoma may have elevated intraocular pressure. Hypertension causes damages to intraocular structures and affects the Schlemm's canal, collector channels, trabecular meshwork, and optic nerve's molecular structures. An important gene that is defective in patients with glaucoma is CYP1B1, a gene associated with optic nerve deterioration. CYP1B1is a key enzyme involved in the metabolism of exogenous and endogenous compounds. Also, it is critical in the detoxification of pre-carcinogens, such as polycyclic aromatic hydrocarbons and estrogen. It catalyzes their conversion into metabolites subsequently eliminated from the body. In malignant tumors, the CYP1B1 promoter is hypomethylated. CYP1B1 overexpression results in the conversion of estrogens to quinone forms, which bind with DNA and create a predisposition for cancer in several organs, such as the brain, breast, and ovary. Increased cytokine interleukin-6 and leptin lead to elevated CYP1B1 activity, which possibly causes cancer. In addition, the expression of aromatic hydrocarbon receptors is increased in tumor tissues, and it elevates oxidative stress and cell growth. TCGA database analysis showed increased survival at bladder and renal carcinoma when CYP1B1 expression is low. Therefore, alteration of CYP1B1 expression may suggest a therapeutic benefit for multiple diseases such as glaucoma and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.